Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis
News provided by
Share this article
Share this article
EXTON, Pa., Jan. 29, 2021 /PRNewswire/ Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering,
New Research on Emerging Markets in Dermatology Reveals Vast Potential for Pipeline Agents
US dermatologists lack of satisfaction with current treatment options in hidradenitis suppurativa and alopecia areata paves the way for advanced systemic agents to disrupt each market
News provided by
Share this article
Share this article
EXTON, Pa., Jan. 21, 2021 /PRNewswire/ Spherix recently surveyed 101 US dermatologists and followed up with eleven qualitative interviews (including two with industry key opinion leaders) in order to assess the current and future treatment paradigm of hidradenitis suppurativa (HS) and alopecia areata (AA) patients.
Spherix s new
Market Dynamix™ service, focusing on emerging dermatologic conditions, highlights disease states in which a paradigm shift is anticipated within the next three to five years. The combination of qualitative and quantitative research included in the service evaluates market size, current treatment approaches, unmet needs,
Share this article
Share this article
EXTON, Pa., Jan. 20, 2021 /PRNewswire/ Two 2020 European Medical Agency (EMA) approvals, Takeda s Entyvio SC and Celltrion Healthcare s infliximab biosimilar, Remsima SC, have captured notable shares among EU5 IBD patients, according to Spherix s recent report,
RealTime Dynamix™: Inflammatory Bowel Disease (EU). The report sampled 246 EU5 gastroenterologists in November and December of 2020. While both new, subcutaneous market entrants have mostly gained prescribing momentum by cannibalizing their corresponding IV formulations, AbbVie s Humira stands out with its continual decline in EU5 IBD utilization.
Entyvio SC has managed to capture a sizeable portion of both the EU5 ulcerative colitis (UC) and Crohn s disease (CD) markets. This uptake is supported by the established familiarity that gastroenterologists have with Entyvio s IV formulation. Not surprisingly, Takeda is experiencing some cannibalization of Entyvio IV with the introdu